Alzamend Neuro, Inc.
ALZNNASDAQHealthcare● Active
$1.16
+$0.05(+4.50%)
Market Cap$3642238
P/E Ratio—
52W High$3.6
52W Low$0.84
Alzamend Neuro, Inc. (ALZN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALZN · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 11, 2026EPS Actual
-$0.58
Est. -$0.53 · -9.4%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 11, 2026
After Market Close
▼ Miss EPS
ALZN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 28, 2026 | -$0.67 | — | — | — | — | — |
| ▼ Q1 FY2026 | Mar 11, 2026 | -$0.53 | -$0.58 | -9.4% | — | — | — |
| ▲ Q4 FY2025 | Dec 9, 2025 | -$0.83 | -$0.30 | +63.9% | — | — | — |
| ▲ Q3 FY2025 | Sep 10, 2025 | -$3.69 | -$1.28 | +65.3% | — | — | — |
| ▲ Q1 FY2025 | Mar 10, 2025 | -$2.61 | -$1.71 | +34.5% | — | — | — |
| ▲ Q4 FY2024 | Dec 11, 2024 | -$21.42 | -$3.60 | +83.2% | — | — | — |
| ▼ Q3 FY2024 | Sep 11, 2024 | -$2.38 | -$11.25 | -372.7% | — | — | — |
| ▼ Q3 FY2024 | Jul 30, 2024 | -$2.75 | -$13.35 | -385.4% | $0.00B | — | — |
Q3 FY2026
Jul 28, 2026
EPS Actual
—
EPS Est.
-$0.67
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 11, 2026Miss
EPS Actual
-$0.58
EPS Est.
-$0.53
EPS Surpr.
-9.4%
Revenue
—
Q4 FY2025
Dec 9, 2025Beat
EPS Actual
-$0.30
EPS Est.
-$0.83
EPS Surpr.
+63.9%
Revenue
—
Q3 FY2025
Sep 10, 2025Beat
EPS Actual
-$1.28
EPS Est.
-$3.69
EPS Surpr.
+65.3%
Revenue
—
Q1 FY2025
Mar 10, 2025Beat
EPS Actual
-$1.71
EPS Est.
-$2.61
EPS Surpr.
+34.5%
Revenue
—
Q4 FY2024
Dec 11, 2024Beat
EPS Actual
-$3.60
EPS Est.
-$21.42
EPS Surpr.
+83.2%
Revenue
—
Q3 FY2024
Sep 11, 2024Miss
EPS Actual
-$11.25
EPS Est.
-$2.38
EPS Surpr.
-372.7%
Revenue
—
Q3 FY2024
Jul 30, 2024Miss
EPS Actual
-$13.35
EPS Est.
-$2.75
EPS Surpr.
-385.4%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2028 | $-0.77 | $-0.77 | $-0.77 | 1 |
| Q1 FY2028 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Q4 FY2027 | $-0.78 | $-0.78 | $-0.78 | 1 |
| Q3 FY2027 | $-0.75 | $-0.75 | $-0.75 | 1 |
| Q2 FY2027 | $-0.63 | $-0.63 | $-0.63 | 1 |
| Q1 FY2027 | $-0.64 | $-0.64 | $-0.64 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 11, 2026 | -9.4% | $2.14 | $2.18 | +1.87% |
| ▲ Q4 FY2025 | Dec 9, 2025 | +63.9% | $2.25 | $2.17 | -3.56% |
| ▲ Q3 FY2025 | Sep 10, 2025 | +65.3% | $2.37 | $2.35 | -0.84% |
| ▲ Q1 FY2025 | Mar 10, 2025 | +34.5% | $6.84 | $6.38 | -6.73% |
| ▲ Q4 FY2024 | Dec 11, 2024 | +83.2% | $11.07 | $10.80 | -2.44% |
| ▼ Q3 FY2024 | Sep 11, 2024 | -372.7% | $18.99 | $18.27 | -3.79% |
| ▼ Q3 FY2024 | Jul 30, 2024 | -385.4% | $35.91 | $30.60 | -14.79% |
| ▼ Q1 FY2024 | Mar 25, 2024 | -10587.5% | $96.30 | $90.90 | -5.61% |
Q1 FY2026+1.87%
Report Date
Mar 11, 2026
EPS Beat/Miss
-9.4%
Price Before
$2.14
Price After
$2.18
Q4 FY2025-3.56%
Report Date
Dec 9, 2025
EPS Beat/Miss
+63.9%
Price Before
$2.25
Price After
$2.17
Q3 FY2025-0.84%
Report Date
Sep 10, 2025
EPS Beat/Miss
+65.3%
Price Before
$2.37
Price After
$2.35
Q1 FY2025-6.73%
Report Date
Mar 10, 2025
EPS Beat/Miss
+34.5%
Price Before
$6.84
Price After
$6.38
Q4 FY2024-2.44%
Report Date
Dec 11, 2024
EPS Beat/Miss
+83.2%
Price Before
$11.07
Price After
$10.80
Q3 FY2024-3.79%
Report Date
Sep 11, 2024
EPS Beat/Miss
-372.7%
Price Before
$18.99
Price After
$18.27
Q3 FY2024-14.79%
Report Date
Jul 30, 2024
EPS Beat/Miss
-385.4%
Price Before
$35.91
Price After
$30.60
Q1 FY2024-5.61%
Report Date
Mar 25, 2024
EPS Beat/Miss
-10587.5%
Price Before
$96.30
Price After
$90.90
Avg Beat Reaction-3.39%
Avg Miss Reaction-5.58%
Beat Rate4 / 8 quarters
Largest Move-14.79% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALZN ends December
Alzamend Neuro, Inc. (ALZN) most recently reported earnings on March 11, 2026 for Q1 FY2026, posting EPS of $-0.58 — missing the analyst consensus of $-0.53 by -9.4%. The next ALZN earnings date is expected around September 1, 2026.
Each quarter, investors track ALZN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALZN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALZN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALZN earnings · 5 questionsAlzamend Neuro, Inc.'s next earnings report is expected around September 1, 2026. ALZN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALZN historically reports after market close (AMC).
ALZN earnings datewhen is ALZN earningsALZN next earnings datewhen does ALZN report earningsALZN earnings calendar
▸ Source: FMP · Alzamend Neuro, Inc. SEC filings · US GAAP · Alzamend Neuro, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026